Our results show that the MapQuantTM assay, based on mRNA expression assay, provides an objective and quantitative assessment of Estrogen receptor, Progesterone receptor and HER2 status in invasive breast cancer. This evidence concerns the gene PGR and invasive breast carcinoma.